GlassScriptPhysician profile
Shawn C Mclane
NPI 1194741959
$1,945.20
in general payments reported to CMS, 2019-2025
25 companies · $25.58 in 2025
The $25.58 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $214 · 2021: $389 · 2022: $578 · 2023: $329 · 2024: $64.47 · 2025: $25.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $418.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $370.88 | 2019-2024 | Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $196.19 | 2020-2023 | Dupixent |
| Mallinckrodt Hospital Products INC. | $159.03 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.46 | 2019-2023 | Ofev |
| Novartis Pharmaceuticals Corporation | $134.25 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $124.06 | 2019-2022 | |
| Amgen INC. | $98.07 | 2021-2023 | Tezspire |
| Insmed, INC. | $98.00 | 2019-2022 | |
| United Therapeutics Corporation | $96.15 | 2019-2022 | |
| Genzyme Corporation | $84.33 | 2019-2024 | |
| Mylan Specialty L.P. | $55.82 | 2020-2022 | |
| Genentech USA, INC. | $54.52 | 2019-2023 | Xolair |
| Actelion Pharmaceuticals US, INC. | $45.84 | 2022 | |
| Paratek Pharmaceuticals, INC. | $37.07 | 2021 | |
| Mallinckrodt Enterprises LLC | $36.35 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $28.61 | 2023 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $28.42 | 2023 | Glassia |
| Atricure, INC. | $25.58 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Grifols USA, LLC | $24.58 | 2023 | Prolastin-C Liquid |
| Electromed, INC. | $23.44 | 2019-2021 | |
| Baxter Healthcare | $20.23 | 2022 | |
| Vifor Pharma, INC. | $16.88 | 2024 | Zemaira |
| Pharming Healthcare, INC. | $15.42 | 2023 | Ruconest |
| Sandoz INC. | $12.24 | 2022 | |
| Circassia INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Mclane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.